Published in NPJ Biofilms Microbiomes on September 28, 2017
Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother (1985) 7.31
Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol (2003) 7.29
The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol (1999) 7.19
Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature (2002) 7.08
A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature (2003) 6.06
Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents (2010) 5.18
Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis (1998) 4.82
Bacterial resistance to antibiotics: the role of biofilms. Prog Drug Res (1991) 3.41
A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2000) 2.91
Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog (2008) 2.71
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol (2009) 2.53
Characterization of colony morphology variants isolated from Pseudomonas aeruginosa biofilms. Appl Environ Microbiol (2005) 2.41
Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev (2002) 2.27
Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis (1999) 2.18
Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2001) 1.96
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (2004) 1.91
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest (2003) 1.86
Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol (2005) 1.48
Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother (2005) 1.48
Analysis of a marine phototrophic biofilm by confocal laser scanning microscopy using the new image quantification software PHLIP. BMC Ecol (2006) 1.37
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol (2006) 1.34
Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections. Mol Med Today (1999) 1.33
ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect (2015) 1.24
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother (2001) 1.24
A new device for rapid evaluation of biofilm formation potential by bacteria. J Microbiol Methods (2007) 1.20
Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2013) 1.17
A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc (2010) 1.07
Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother (2014) 1.05
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax (2012) 1.04
Antibiotic treatment of CF lung disease: from bench to bedside. J Cyst Fibros (2011) 0.96
BioTimer Assay, a new method for counting Staphylococcus spp. in biofilm without sample manipulation applied to evaluate antibiotic susceptibility of biofilm. J Microbiol Methods (2008) 0.95
A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros (2008) 0.92
Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis. Sci Rep (2015) 0.86
The BioFilm Ring Test: a Rapid Method for Routine Analysis of Pseudomonas aeruginosa Biofilm Formation Kinetics. J Clin Microbiol (2015) 0.82
Prevalence and antimicrobial susceptibility of Pseudomonas aeruginosa mucoid and non-mucoid type. Southeast Asian J Trop Med Public Health (2004) 0.81
Effect of biosurfactants on Pseudomonas aeruginosa and Staphylococcus aureus biofilms in a BioFlux channel. Appl Microbiol Biotechnol (2016) 0.80
Rapid depletion of dissolved oxygen in 96-well microtiter plate Staphylococcus epidermidis biofilm assays promotes biofilm development and is influenced by inoculum cell concentration. Biotechnol Bioeng (2009) 0.79
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev (2015) 0.79
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin Microbiol Rev (2014) 0.79
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol (2010) 0.77
Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. J Cyst Fibros (2014) 0.77
Antimicrobial susceptibility differences among mucoid and non-mucoid Pseudomonas aeruginosa isolates. GMS Hyg Infect Control (2014) 0.77
Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions. Pathog Dis (2015) 0.77
Characterization of Staphylococcus aureus small colony variant strains isolated from Italian patients attending a regional cystic fibrosis care centre. New Microbiol (2015) 0.76
Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann Pharmacother (2012) 0.75
Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros (2014) 0.75
Successful prevention of scedosporiosis after lung transplantation in a cystic fibrosis patient by combined local and systemic triazole therapy. Med Mycol Case Rep (2013) 0.83
Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization. BMC Infect Dis (2017) 0.75
Listeria monocytogenes endophthalmitis - case report and review of risk factors and treatment outcomes. BMC Infect Dis (2016) 0.75
Portable UV light as an alternative for decontamination. Am J Infect Control (2014) 0.75